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Abstract  
Atorvastatin, potent lipid lowering agent, has beneficial effects in enhancing insulin 
sensitivity. Its role in improving liver enzymes is controversial. This study aimed to 
investigate the effects of atorvastatin in improving liver enzymes. Our  study included 62 
patients with diabetes type 2. They were assigned into two groups: experimental group of 33 
patients who received atorvastatin treatment for 2 months and control group of 29 patients. 
Blood samples were obtained before and after the experiment. Lipid profile, glucose and liver 
function test profile were observed. The results showed that both cholesterol and triglycerides 
levels decreased significantly (p value 0.019 and 0.025 respectively). No significant changes 
in glucose level were observed (p value>0.05). Of liver enzyme profile, AST decreased 
significantly (p value 0.05). ALP, CKNAC, total proteins and total bilirubin did not show 
significant changes (p value >0.05). 
Conclusion: Atorvastatin treatment decreased cholesterol and triglycerides, and improved 
liver enzymes in diabetic type 2 patients. 
 
Keywords: Atorvastatin, cholesterol, triglycerides, glucose, liver, AST, ALP, CKNAC, total 
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Introduction  
Statins have been widely implicated clinically as lipid lowering agents to reduce 
morbidity and mortality from coronary artery disease. Statins work as inhibitors of the rate-
limiting enzyme, 3 -hydro xy-3-me thylglutaryl-CoA (HMG-CoA) reductase, in cholesterol 
biosynthesis (Doustar Yousef, 2011).  
 Statins's  beneficial effects on atherosclerosis are mediated by decreased low-density 
lipoprotein (LDL) cholesterol and improving endothelial function (Kwang Kon Koh, 2010).  
 Several researchers indicated that lipophilic statins have pleiotropic actions that might 
cause unfavorable metabolic effects such as reduction of insulin secretion and exacerbation of 
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insulin resistance (Kanda M, 2006; Nakata M, 2006). Furthermore, other studies pointed out 
the possibility that lipophilic statins might increase the rate of new onset diabetes (Sever PS, 
2003; Ridker PM, 2008).  
 In a study conducted by Eliasson B (2011), it was found that blood lipid levels were 
lowered due to use of atorvastatin among patients with type 2 diabetes, while Athyros VG 
(2011) demonstrated that atorvastatin significantly improved liver functions by decreasing 
liver enzymes in patients with already abnormal liver test.  
Materials and Methods 
Study Design 
 The study design is an observational clinical study at Prince Rashed Military Hospital.  
Clinical Setting   
 Sample recruitment was in the period between July 2010, and December 2010. The 
study was conducted at healthcare facility in the northern of Jordan; Prince Rashed Military 
Hospital. 
Subject Description 
 The study included 62 diabetic patients who were randomly recruited from the 
Medical Clinics of the PRH. 
 Sample population was recruited depending on the following inclusion and exclusion 
criteria: 
Inclusion Criteria 
Adult patients aged 18 years or more, diagnosed with type 2 diabetes. 
Exclusion Criteria 
1. Presence of liver disease. 
2. Type 1 diabetes.  
3. Elevation of transaminase levels >1.5 times the upper normal limit at baseline. 
4. Elevation of creatine kinase (CK) level>1.5 times the upper normal limit at baseline. 
5. Presence of a condition of atrioventricular block and/or sinus bradycardia. 
6. Presence of acute or chronic renal failure. 
7. Evidence of electrolyte disturbances. 
8. Cases of acute cerebrovascular disease or myocardial infarction within the preceding 
three months. 
9. Evidence of alcohol abuse. 
10. A condition of hypothyroidism. 
11. Evidence of myopathy. 
12. Pregnant patients. 
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13. Patients who had any medication changes during the two months preceding 
participation. 
14. Previous treatment with anti-hyperlipidemia drugs during the 4 weeks before 
conducting the study. 
Data Collection and Patient Interviews 
A previously validated questionnaire was utilized for appropriate data collection and 
further statistical analysis. Each patient’s medical profile of the medical clinic was reviewed. 
Statistical Analysis 
 Data were analyzed using SPSS version 15. Frequencies means and standard 
deviations were used to describe data wherever appropriate. Chi-Square cross tabs were used 
to investigate the significance of difference between study and control groups. Binary logistic 
regression was used to determine factors associated with glycemic control. P –value of <0.05 
was considered statistically significant. 
Results  
Clinical variables associated with diabetes among study and control groups 
 The study included 62 diabetic patients distributed into two groups: control group 
(n=29 (46.8%)) and study group (n=33 (53.8%)). Among the variables investigated, two 
variables were significant glaucoma (p value 0.005) and family history of cardiac disease (p 
value 0.048). The other variables were not significant (p value >0.05) (table 1). 
 
 
Table 1: Clinical variables associated with diabetes and their significance 
Variable  Study group  P value 
Control  Study  
FHTD  
YES  
NO 
 
5 
24 
 
3 
30 
 
0.282 
Glaucoma  
YES  
NO 
 
11 
18 
 
20 
13 
 
0.005 
HD 
YES  
NO 
 
3 
26 
 
0 
33 
 
0.144 
ED 
YES  
NO 
 
9 
20 
 
4 
29 
 
0.162 
PNP 
YES  
NO 
 
1 
28 
 
 
0 
33 
 
0.468 
FHDM 
YES  
NO 
 
18 
11 
 
23 
10 
 
0.357 
FHTD 
YES  
NO 
 
6 
23 
 
2 
31 
 
0.091 
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FHCD 
YES  
NO 
 
2 
27 
 
9 
24 
 
0.048 
HEPATIC 
YES  
NO 
 
6 
23 
 
7 
26 
 
1.000 
PNP 
YES 
  
NO 
 
21 
 
8 
 
25 
 
8 
 
 
0.780 
BP 
YES  
NO 
 
16 
13 
 
20 
13 
 
0.797 
DFU 
YES  
NO 
 
2 
27 
 
3 
30 
 
1.000 
Dyslipidemia  
YES  
NO 
 
1 
28 
 
0 
33 
 
0.48 
 
Personal parameters among study and control groups  
Table 2 shows a comparison between study group and control group for the following 
factors: age, BMI, WC, SBP and DBP. WC was the only variable with significance between 
study and control groups (p value 0.033) while the other variables were not significant (p 
value > 0.05) (table 2). 
 
Table 2: Personal parameters among study and control groups 
Variable          Study group         Control group P value 
Mean (N =33)  +/- SD Mean (N= 29) +/- SD 
Age 56.6333 12.63679 
 
57.3333 11.32082 0.849 
WC 100.55 4.96 97.206 6.07 0.033 
BMI 35.3294 29.19011 27.8111 8.15858 0.189 
SBP 136.4286 21.80966 134.2857 15.01322 0.692 
DBP 84.4828 14.03725 83.2759 8.89180 0.705 
 
Chemical parameters between study and control group 
The following biochemical parameters were investigated among study and control 
groups and showed no significance (p value >0.05): glucose, total protein, AST. Cholesterol, 
triglyceride, HDLC2, LDLC2, and total bilirubin. The following variables were significant: 
ALP (0.019), CK-NAC (0.048), and amylase (0.043) (table 3).  
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Table 3: Chemical parameters between study and control group 
Variable          Study group         Control group P value 
Mean (N =33)  +/- SD Mean (N= 29) +/- SD 
Glucose 229.79 73.57 245.81 94.18 0.413 
ALP 88.12 24.69 103.28 25.57 0.019 
TP 8.22 0.44 8.37 0.39 0.372 
AST   20.96 12.10 26.34 16.50 0.194 
CKNAC  105.33 59.75 76.47 46.64 0.048 
Amylase  38.73 21.03 59.63 28.63 0.043 
Cholesterol  219.89 60.96 217.24 44.18 0.837 
TG 231.65 126.14 263.75 217.90 0.466 
HDLC2 51.13 16.82 43.08 7.66 0.064 
LDLC2 120.90 48.24 118.20 41.03 0.829 
      
LDH 334.73 85.93 322.13 75.42 0.619 
Total Bilirubin 0.38 0.192 0.44 0.199 0.290 
 
The effects of Atorvastatin on chemical parameters after the end of experiment 
After the end of the experiment, atorvastatin was able to decrease significantly the 
level of cholesterol (p value 0.019), triglycerides (p value 0.025). There was no significant 
reduction in the level of HDLC and LDLC (P value > 0.05). The glucose level was also 
reduced insignificantly (P value > 0.05). The profile of liver enzymes showed significant 
decrease in the level of AST (P value 0.05), while there was insignificant decrease in the 
level of ALP (P value > 0.05), and insignificant increase in the level of CK NAC (P value > 
0.05). Both of total protein and total bilirubin were decreased insignificantly (P value > 0.05) 
(table 4).  
Table 4: The effects of Atorvastatin on chemical parameters after the experiment 
 
Discussion  
The present study is an observational study. It was conducted among diabetic groups. 
Our data demonstrated that treatment with atorvastatin, as a lipid lowering agent, reduced the 
blood concentration of cholesterol significantly after the end of two months treatment (p 
value 0.019). Triglyceride level was also decreased significantly (p value 0.025). The levels 
of HDLC2 do not increase significantly (p value 0.325) and the levels of LDLC do not 
Variable         before Study       After study    P value 
Mean  +/- SD Mean  +/- SD 
Cholesterol     220.757 55.4 201.909 53.63 0.019 
Triglyceride  265.018 210.41 223 178.67 0.025 
HDLC2  44.75 9.48 47.41 11.71 0.352 
LDLC  121.63 42.011 112.51 37.82 0.349 
Glucose 229.79 76.87 221.78 82.36 0.571 
ALP 88.12 24.69 93.00 33.38 0.638 
TP 8.22 0.44 7.98 0.32 0.319 
AST   20.69 12.10 14.97 7.86 0.05 
CKNAC  105.33 59.75 92.79 54.93 0.663 
Total bilirubin 0.38 0.192 0.3048 0.18 0.290 
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decrease significantly (p value 0.349). The findings for cholesterol and triglycerides indicate 
that statins in general are working as inhibitors for 3 -hydro xy-3-me thylglutaryl-CoA 
(HMG-CoA) reductase, in cholesterol biosynthesis and cholesterol is more sensitive for statin 
treatment (Doustar Yousef, 2011, Kwang Kon Koh, 2010). Our findings are consistent results 
reported by Eliasson B (2011). Furthermore, non significant changes in the levels of HDLC2 
and LDLC are explained by the need for long term treatment of atorvastatin as indicated by 
Athyros VG (2011).  
 Treatment by atorvastatin reduced glucose level insignificantly (p value 0.571). In our 
study, glucose level decreased but not significantly while , a study reported by Anagnostis P 
(2011) showed increased level after statin therapy.  
 Our results showed decreased level of AST significantly (p value 0.05). This finding 
showed improvement of liver enzymes and consistent with reported findings of Athyros VG 
(2011). It was also found no significant decrease in liver ALP, total proteins, CKNAC and 
total bilirubin (p value > 0.05 for all). These findings can be attributed to the fact that most 
participants were not hepatic patients , according to Athyros VG (2011), patients with 
moderate hepatic disease has get more benefit from statin treatment.  
Conclusion 
 Treatment by atorvastatin decreased cholesterol, triglycerides, and improved liver 
enzymes in type 2 diabetic patients and long term study is needed to assess metabolic 
changes. 
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